¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cardiovascular devices associated with adverse incidents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® cardiovascular system ÇÑ±Û ½ÉÀåÇ÷°ü°è
¼³¸í   
  ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇϴ ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼­ À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® adverse effect ÇÑ±Û ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
¼³¸í   
  ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇϴ °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇϴ Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, Æ¯È÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀΠ¿ªÈ¿°ú·Î¼­ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • adverse effect
    À¯ÇØÈ¿°ú
  • adverse reaction
    À¯ÇعÝÀÀ
  • arteriosclerotic cardiovascular disease
    µ¿¸Æ°æÈ­½É(Àå)Ç÷°üº´
  • cardiovascular
    ½ÉÀåÇ÷°ü-
  • cardiovascular collapse
    ½É(Àå)Ç÷°üÇãÅ»
  • cardiovascular cycle
    ½ÉÀåÇ÷°üÁÖ±â
  • cardiovascular disease
    ½É(Àå)Ç÷°üÁúȯ
  • cardiovascular drift
    ½É(Àå)Ç÷°ü°èÀ¯µ¿, ½ÉÇ÷°ü°èÇ¥·ù
  • cardiovascular shunt
    ½ÉÀåÇ÷°ü¼ÇÆ®
  • cardiovascular system
    ½ÉÀåÇ÷°ü°èÅë, ½ÉÇ÷°ü°è
  • functional cardiovascular disease
    ±â´É¼º½É(Àå)Ç÷°üº´
  • antibiotic-associated
    Ç×»ýÁ¦°ü·Ã-
  • associated defect
    ¿¬°üÀå¾Ö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse effect
    (¢¡ adverse event) À¯ÇذæÇè
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • arteriosclerotic cardiovascular disease
    µ¿¸Æ°æÈ­½ÉÀåÇ÷°üº´
  • cardiovascular
    ½ÉÀåÇ÷°ü-
  • cardiovascular collapse
    ½ÉÀåÇ÷°üÇãÅ»
  • cardiovascular cycle
    ½ÉÀåÇ÷°üÁÖ±â
  • cardiovascular disease
    ½ÉÀåÇ÷°üº´
  • cardiovascular system
    ½ÉÀåÇ÷°ü°èÅë
  • functional cardiovascular disease
    ±â´É½ÉÀåÇ÷°üº´
  • antibiotic-associated
    Ç×»ýÁ¦°ü·Ã-
  • adeno-associated virus
    ¾Æµ¥³ë¹ÙÀÌ·¯½ºÀÇÁ¸¹ÙÀÌ·¯½º
  • associated defect
    ¿¬ÇÕ°áÇÔ, ¿¬ÇÕ°á¼Õ, ¼ö¹ÝÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Intrauterine devices
    Àڱó»ÀåÄ¡(í­ÏàÒ®íûöÇ)
  • functional cardiovascular disease
    ±â´É¼º ½ÉÇ÷°üº´.
  • I region-associated antigen
    Ir¿¬°üÇ׿ø
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã(¡­Î¼æá) ¹ÙÀÌ·¯½º.
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã(¡­Î¼æá) ¹ÙÀÌ·¯½º.
  • adeno-associated virus
    ¾Æµ¥³ë(¹ÙÀÌ·¯½º) ÀÇÁ¸ ¹ÙÀÌ·¯½º
  • age-associated memory impairment
    ¿¬·É°ü·Ã ±â¾ï·Â Àå¾Ö(¼Õ»ó)
  • antibiotic-associated colitis/diarrhea
    Ç×»ýÁ¦À¯¹ß´ëÀå¿°, Ç×»ýÁ¦À¯¹ß¼³»ç
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • gut-associated lymphatic tissue (GALT)
    Àå-¿¬°ü ¸²ÇÁÁ¶Á÷
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • devices
    ÀåÄ¡¡ì±â°èÀåÄ¡¡í, º¸À屸(ÜÍíûÎý), °í¾È.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reactions
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ.
  • drug reactions, adverse
    ¾à¹°¹ÝÀÀ(¡­Úãëë), ºÎÀÛ¿ë(ÜùíÂéÄ)
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ºÎÀÛ¿ë
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ¾àÇØ(å·úª)¹ÝÀÀ.[¾à¸®]ºÎÀÛ¿ë, ºÒ¿øÀÛ¿ë.
  • arteriosclerotic cardiovascular disease
    µ¿¸Æ°æÈ­¼º ½ÉÇ÷°üº´(¡­ãýúìηܻ).
  • cardiovascular
    ½ÉÇ÷°üÀÇ.
  • cardiovascular anesthesia
    ½ÉÇ÷°ü¸¶Ãë
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adenovirus-associated virus
    ¾Æµ¥³ë¹ÙÀÌ·¯½º¿¬°è(ææÍ¨) ¹ÙÀÌ·¯½º
  • I region-associated protein
    I ºÎÀ§¿¬°ü(Ý»êÈ֤μ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • microtubule-associated proteins
    ¹Ì¼Ò°ü ¿¬°ü´Ü¹éÁú(Ú°á³Î·æáμӱÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • MALT(mucosa associated lymphoid tissue)
    Á¡¸·°ü·Ã¸²ÇÁÁ¶Á÷
  • cardiovascular
    ½ÉÇ÷°üÀÇ
  • cardiovascular system
    ½ÉÀåÇ÷°ü°è
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse reaction
    ºÎÀÛ¿ë, À¯ÇعÝÀÀ, À¯ÇØÀÛ¿ë, ¿ª¹ÝÀÀ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACVD acute cardiovascular disease, atherosclerotic cardiovascular disease
ASCVD arteriosclerotic cardiovascular disease; atherosclerotic cardiovascular disease
CVI cardiovascular incident; cardiovascular insufficiency; cerebrovascular incident; cerebrovascular ins...
CVR cardiovascular-renal; cardiovascular-respiratory; cephalic vasomotor response; cerebrovascular resis...
CVS cardiovascular surgery; cardiovascular system; challenge virus strain; chorionic villi sampling; cle...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CDRH Center for Devices and Radiological Health
CVAD Central venous access devices
SCD Sequential Compression Devices
VAD Venous access devices
the SMDA the Safe Medical Devices Act of 190
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • Y71
    Cardiovascular devices associated with adverse incidents
    À¯ÇØ»ç°Ç°ú °ü·ÃµÈ ½ÉÀåÇ÷°ü ÀåÄ¡
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cardiovascular
    ½ÉÇ÷°üÀÇ
    ½ÉÀå°ú Ç÷°ü¿¡ °üÇÑ.
  • cardiovascular collapse
    ½É Ç÷°ü ÇãÅ», ¼øÈ¯ ÇãÅ»
  • cardiovascular syphilis
    ½ÉÀå Ç÷°ü ¸Åµ¶
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • adverse event
    À¯ÇØ »ç·Ê
  • adverse loading
    À¯ÇØ ÇÏÁß, ÇØ·Î¿î ÇÏÁß
  • adverse selection
    ¿ª ¼±ÅÃ
  • systemic adverse effect
    Àü½Å¼º ºÎÀÛ¿ë
  • adeno-associated virus
    ¾Æµ¥³ë °ü·Ã ¹ÙÀÌ·¯½º
  • associated
    µ¿¹ÝÀÇ, ¼ö¹ÝÀÇ, °ø¾×ÀÇ, ¿¬ÇÕÀÇ
  • associated symptom
    °ü·Ã Áõ»ó
  • HIV associated periodontal disease
    HIV¿Í °ü·ÃµÈ Ä¡ÁÖ Áúȯ
  • lateral cord and associated anterior cornual syndrome
    Ãø»è µ¿Ãø Àü°¢ ÁõÈıº
  • self-associated rheumatoid factor complex

    self-care (ÀÚ°¡ Ä¡·á

CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
adverse Harmful.
(18 Nov 1997)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
adverse effect This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical.
(09 Oct 1997)
adverse event A toxic reaction to a medical therapy.
(09 Oct 1997)
adverse reaction Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen.
(05 Mar 2000)
no-observed-adverse-effect level The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed)
(12 Dec 1998)
event, adverse In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug.
(12 Dec 1998)
cardiovascular <cardiology, physiology> Pertaining to the heart and blood vessels.
(18 Nov 1997)
cardiovascular abnormalities Congenital structural abnormalities of the cardiovascular system.
(12 Dec 1998)
cardiovascular agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
(12 Dec 1998)
cardiovascular deconditioning A change in cardiovascular function, especially after periods of actual or simulated weightlessness or diminished power or strength, probably related to the shift of a quantity of blood from the lower limbs to the thorax, resulting in reflex diuresis and a reduction of blood volume.
(12 Dec 1998)
cardiovascular physiology Functions and activities of the cardiovascular system as a whole or of any of its parts.
(12 Dec 1998)
cardiovascular radiology The clinical subspecialty of radiology concerned with diagnosis and treatment of diseases of the vascular system.
(05 Mar 2000)
cardiovascular surgery The use of surgery to fix disorders of the heartand/or blood vessels.
(09 Oct 1997)
cardiovascular surgical procedures Surgery performed on the heart or blood vessels.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cardiovascular
    ½ÉÀå Ç÷°üÀÇ
  • adverse
    ¿ªÀÇ, ºÒ¿îÇÑ, ¹Ý´ëÇÏ´Â
  • associated
    ¿¬ÇÕÇÑ
  • adverse
    ¿ªÀÇ;°Å²Ù·ÎÀÇ;¹Ý´ëÀÇ;ÀûÀǰ¡ ÀÖ´Â;ºÒ¸®ÇÑ
  • associated
    ¿¬ÇÕÇÑ;Á¶ÇÕÀÇ;ÇÕµ¿ÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á